Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Iressa May Pave Way For EGFR Inhibitors In Adjuvant Lung Cancer

Executive Summary

Study done in China may prompt a change the standard of care in the US to include earlier testing for EGFR mutations after surgery, but is unlikely to change treatment protocols until overall survival data are available.

Advertisement

Related Content

AstraZeneca Upbeat On China Prospects For New Products
AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market
AstraZeneca's Iressa Use Narrowed: No New Commercial Patients

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC098764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel